Sun Pharmaceutical Industries Limited
A single plant registered with the FDA to make drugs for the US market. Below is where it is and the drugs whose FDA labels list this site as performing a manufacturing step — so if this plant has a problem, these are the products that could be affected.
- Country
- India
- Registered address
- Plot No. A-41, Industrial Area Phase-VIII A, S.A.S. Nagar, Mohali, Punjab 160071, India (IND)
- Operations here
- analysismanufacture
- FDA identifiers
- FEI 3002807979 · DUNS 650456002
FDA inspection history
Outcomes of closed FDA inspections at this site (drug and biologic program areas).
- OAIDrug Quality Assurance2022-08-12
- VAIDrug Quality Assurance2020-02-07
- NAIDrug Quality Assurance2019-05-10
- NAIDrug Quality Assurance2018-09-14
- VAIDrug Quality Assurance2016-11-16
- OAIDrug Quality Assurance2012-12-12
- VAIDrug Quality Assurance2011-06-22
Drugs this plant is listed as making
9 distinct drugs across 22 products name this site in their FDA label.
- Atorvastatin CalciumSun Pharmaceutical Industries Inc.
- Diltiazem hydrochlorideSun Pharmaceutical Industries, Inc.
- droxidopaSun Pharmaceutical Industries, Inc.
- DuloxetineSun Pharmaceutical Industries, Inc.
- fenofibrateSun Pharmaceutical Industries, Inc.
- MesalamineSun Pharmaceutical Industries Inc.
- Pantoprazole SodiumNorthStar RxLLC
- RanolazineSun Pharmaceutical Industries, Inc.
- Risedronate SodiumSun Pharmaceutical Industires Inc.
Sources:the establishment's name, address, and country from FDA's Drug Establishments Current Registration Site (DECRS); the drug-to-facility links from DailyMed SPL drug labels, matched by the facility's DUNS number; inspection outcomes from the FDA Data Dashboard, matched by FEI; shortage status from FDA's drug shortage database. More on how this is built. Educational only.